AJW Stock Overview
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AnGes, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.24 |
| 52 Week High | JP¥0.94 |
| 52 Week Low | JP¥0.24 |
| Beta | 0.57 |
| 1 Month Change | -37.37% |
| 3 Month Change | -40.80% |
| 1 Year Change | -62.81% |
| 3 Year Change | -96.64% |
| 5 Year Change | -96.45% |
| Change since IPO | -98.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| AJW | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.8% | -5.1% | -2.0% |
| 1Y | -62.8% | -21.1% | -0.3% |
Return vs Industry: AJW underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: AJW underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| AJW volatility | |
|---|---|
| AJW Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AJW's share price has been volatile over the past 3 months.
Volatility Over Time: AJW's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 145 | Ei Yamada | www.anges.co.jp |
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University.
AnGes, Inc. Fundamentals Summary
| AJW fundamental statistics | |
|---|---|
| Market cap | €61.00m |
| Earnings (TTM) | -€45.09m |
| Revenue (TTM) | €921.61k |
66.2x
P/S Ratio-1.4x
P/E RatioIs AJW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AJW income statement (TTM) | |
|---|---|
| Revenue | JP¥152.00m |
| Cost of Revenue | JP¥134.00m |
| Gross Profit | JP¥18.00m |
| Other Expenses | JP¥7.46b |
| Earnings | -JP¥7.44b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | -36.96 |
| Gross Margin | 11.84% |
| Net Profit Margin | -4,892.76% |
| Debt/Equity Ratio | 0% |
How did AJW perform over the long term?
See historical performance and comparison